Eli Lilly is opening a path for a limited number of adults with severe obesity to access its experimental weight-loss drug, retatrutide. This comes through a pathway known as compassionate use. While clinical trials show the medication produces significant weight loss, the drug remains unapproved by the FDA and is not generally available to the public.
Criteria for this program are strict. To be considered, a patient must be at least 18 years old, unable to join an ongoing clinical trial, and suffer from refractory obesity. Additionally, applicants must show they have at least two serious health complications related to their obesity and have already discussed all standard treatment options with a medical provider.
Experts note that compassionate use is intended for life-threatening situations where no other treatment paths exist. Because obesity complications are often long-term rather than immediate, meeting these criteria is difficult. Doctors caution that the application process is rigorous, and there is no guarantee that a request for the drug will be approved by the manufacturer.
Patients cannot apply for this access on their own. The process requires a physician to advocate for the request directly to Eli Lilly. If the company agrees to provide the drug, it also requires authorization from both the FDA and an institutional review board.
Medical professionals advise caution regarding unofficial sources. Some individuals seek retatrutide through compounding pharmacies, but these products carry significant risks, including improper dosing or dangerous contaminants. Experts reiterate that the safest path remains waiting for formal clinical trial results and eventual FDA approval, which is expected sometime next year.